It seems to depend on the patient's treatment history and physical condition plus any comorbidities, as well as how long before Pluvicto became available the patient began prostate cancer treatment. Many patients receiving Pluvicto have done so in the recent past because it was only approved by the FDA for general use in 2022, which means that many patients received docetaxel well before Pluvicto. My husband is in this group: his docetaxel was in 2016, while he began Pluvicto in January 2024. Other patients were told they had to undergo chemotherapy before being eligible for Pluvicto (no longer a strict requirement), so that is what they did. On the other hand, some patients are told that docetaxel is an option after Pluvicto.